Remove Development Remove Genetic Engineering Remove Insulin
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

Developing best-in-class speciality enzymes. In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market. Novozymes has a long legacy of enzyme discovery and the ability to genetically engineer these speciality enzymes to be superior.

Drugs 295
article thumbnail

From Gene to Protein: The Journey of Protein Expression Technology

Roots Analysis

Algal Expression System: This expression system is used in genetic engineering, biofuel production, botany. However, this is still a nascent protein expression technology and is relatively less developed than other host systems. It offers excellent experimental control for nutraceuticals and biofuel.

Protein 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98
article thumbnail

What Are the Top 10 Diabetes Medications? A Look at Recent Sales Trends

XTalks

The diabetes medication landscape continues to evolve, driven by advancements in drug development, increasing prevalence of the condition and a growing demand for innovative therapies. The company has also been dealing with imitations of its semaglutide-based products, including the obesity treatment Wegovy.

Sales 105
article thumbnail

Key Trends in the Microbial CMO Market

Roots Analysis

Benefits offered by microbial manufacturing, such as low production costs and faster development timelines, have led many innovators to adopt microbial fermentation for next generation biologics, offering lucrative opportunities for microbial CMOs / CDMOs. Key Growth Drivers 1.